Pfizer (NYSE:PFE) Lowered to “Hold” Rating by Wall Street Zen

Pfizer (NYSE:PFE) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday.

A number of other brokerages have also recently weighed in on PFE. HSBC lifted their price objective on shares of Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. BMO Capital Markets reiterated an “outperform” rating on shares of Pfizer in a report on Tuesday, June 23rd. Morgan Stanley boosted their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. CICC Research initiated coverage on Pfizer in a research report on Thursday, April 16th. They set an “outperform” rating and a $33.00 price objective on the stock. Finally, Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Pfizer currently has an average rating of “Hold” and a consensus target price of $28.82.

Pfizer Price Performance

PFE opened at $24.29 on Friday. The stock’s 50-day moving average price is $25.63 and its 200 day moving average price is $26.23. Pfizer has a 12-month low of $23.11 and a 12-month high of $28.75. The firm has a market cap of $138.45 billion, a price-to-earnings ratio of 18.54 and a beta of 0.35. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.Pfizer’s revenue was up 5.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts expect that Pfizer will post 2.99 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Horizon Financial Services LLC grew its holdings in shares of Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 645 shares during the last quarter. Godfrey Financial Associates Inc. purchased a new stake in shares of Pfizer in the 4th quarter valued at about $26,000. YANKCOM Partnership purchased a new stake in shares of Pfizer in the 4th quarter valued at about $28,000. HFM Investment Advisors LLC boosted its position in shares of Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares during the period. Finally, Evolution Wealth Management Inc. grew its stake in Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 566 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.